Novartis’ PI3K drug hits goal in phase 3 breast cancer trial, laying groundwork for talks with regulators

Novartis’ PI3K inhibitor BYL719 has met the primary endpoint in a phase 3 breast cancer trial. The hit on the progression-free survival endpoint sets Novartis up to start talking to regulators about getting the drug to market.